Compare GXO Logistics Inc (GXO) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GXO Logistics Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? GXO Logistics Inc trades at $45.88 (market cap $5.33B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: GXO Logistics Inc is far larger — about 5.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, GXO Logistics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GXO Logistics Inc for 29 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GXO | MRVI | |
|---|---|---|
Market Cap | $5.33B | $972.90M |
Volume | 961,023 | 4,325,710 |
Sector | Industrials | Health |
52-Week High | $65.59 | $9.00 |
52-Week Low | $44.17 | $2.83 |
Typical Hold Time | 29 Days | 0 Days |
Enterprise Value | $10.68B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GXO Logistics trades at $46.50, down 0.21% with neutral technical signals. The company shows strong revenue growth with 2026 revenue reaching $13.6B and net profit margin improving to 0.96%. Recent earnings beats and strategic partnerships in Europe and aerospace sectors demonstrate operational momentum. Analyst consensus remains strongly bullish with 16 buy ratings and a $66.67 price target, representing 43% upside potential from current levels.
The stock presents compelling value with attractive valuation metrics including P/S of 0.39x, though elevated P/E of 41.15x reflects growth expectations. Key risks include margin pressure from new business at lower incremental margins and competitive industry dynamics. The improving freight industry outlook and GXO's market leadership position support long-term growth prospects despite near-term execution challenges.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GXO Logistics Inc
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
